| Tamarah Fratianni, DO | |
|
1340 N Rim Dr, Flagstaff, AZ 86001-3111 | |
| (928) 774-1873 | |
| (928) 774-5525 |
| Full Name | Tamarah Fratianni |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 34 Years |
| Location | 1340 N Rim Dr, Flagstaff, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689673972 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0123X | Otolaryngology - Facial Plastic Surgery | 3000 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flagstaff Medical Center | Flagstaff, AZ | Hospital |
| Verde Valley Medical Center | Cottonwood, AZ | Hospital |
| Entity Name | Crystal Canyon Ent & Facial Plastic Surgery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285780767 PECOS PAC ID: 6901790146 Enrollment ID: O20040210000400 |
News Archive
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.
A new guide on pancreatic cancer, co-authored by the chair of Surgery at Thomas Jefferson University Hospital, offers a better understanding to patients and caregivers of the unique challenges associated with a diagnosis of pancreatic cancer.
Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).
Today, childhood obesity contributes to a number of potential health risks. Written in an easy to read format, with lively, colorful characters, 'In Moderation' is a children's book that provides simple advice that can significantly reduce over consumption and prevent childhood obesity.
› Verified 9 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.
A new guide on pancreatic cancer, co-authored by the chair of Surgery at Thomas Jefferson University Hospital, offers a better understanding to patients and caregivers of the unique challenges associated with a diagnosis of pancreatic cancer.
Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).
Today, childhood obesity contributes to a number of potential health risks. Written in an easy to read format, with lively, colorful characters, 'In Moderation' is a children's book that provides simple advice that can significantly reduce over consumption and prevent childhood obesity.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tamarah Fratianni, DO 1340 N Rim Dr, Flagstaff, AZ 86001-3111 Ph: (928) 774-1873 | Tamarah Fratianni, DO 1340 N Rim Dr, Flagstaff, AZ 86001-3111 Ph: (928) 774-1873 |
News Archive
Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.
A new guide on pancreatic cancer, co-authored by the chair of Surgery at Thomas Jefferson University Hospital, offers a better understanding to patients and caregivers of the unique challenges associated with a diagnosis of pancreatic cancer.
Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).
Today, childhood obesity contributes to a number of potential health risks. Written in an easy to read format, with lively, colorful characters, 'In Moderation' is a children's book that provides simple advice that can significantly reduce over consumption and prevent childhood obesity.
› Verified 9 days ago
Jacob Stephen Feldman, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1825 W Mary Russell Way, Flagstaff, AZ 86001 Phone: 510-206-1890 | |
Alexander Davis Lund, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 77 W Forest Ave Ste 107, Flagstaff, AZ 86001 Phone: 928-773-2222 Fax: 928-773-2598 | |
Barbara A Burggraaff, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2000 S Thompson St, Flagstaff, AZ 86001 Phone: 928-226-6400 Fax: 928-226-6401 | |
Dr. Daniel Hoehle Downs, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1300 N Rim Dr, Suite B, Flagstaff, AZ 86001 Phone: 928-556-9200 Fax: 928-556-0336 |